Different migraines require different therapy approaches. Migraine is a debilitating disease that can be further complicated when certain symptoms are present.
of patients with migraine have experienced nausea (with or without vomiting) during migraine attacks.1
Oral therapies may be suboptimal when patients have:1
This can cause patients to delay or avoid taking oral medication.
This can impair the absorption of oral therapies.
Consider the route of administration
The American Headache Society recommends a non-oral triptan formulation for the following patient types:2
Migraine with nausea
Tosymra® provides fast migraine pain relief while bypassing the gastrointestinal tract with convenient nasal delivery.3-5
Tosymra® is indicated for the acute treatment of migraine with or without aura in adults.
LIMITATIONS OF USE:
Use only if a clear diagnosis of migraine has been established. Tosymra® is not indicated for the prevention of migraine or treatment of cluster headache.
Peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot-type medication, or another 5-HT1 agonist; concurrent or recent (within 2 weeks) use of a monoamine oxidase (MAO)-A inhibitor; known hypersensitivity to sumatriptan; severe hepatic impairment. These are not all of the contraindications for Tosymra®.
Want more information?
Sign up today to learn more about Tosymra®.
- Newman LC. Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine. Headache. 2013;53 Suppl 1:11-16.
- Rothrock JF, Friedman DI. Information for health care professionals: triptan therapy for acute migraine. American Headache Society. https://americanheadachesociety.org. Accessed October 2020.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.